FORMULATION ARTICLES
-
Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)
Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.
-
From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair
Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.
-
Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking
RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.
-
What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing
RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.
-
Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research
Researchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.
-
Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency
New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.
-
RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.
-
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
Explore the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more.
-
Explore the potential of polymeric nanoparticles (PNPs) as an alternative to viral vectors. PNPs offer design flexibility, enabling larger payloads, targeted release, and minimized side effects.
-
Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.